Navigation Links
Roche Completes Tender Offer for Genentech
Date:3/26/2009

BASEL, Switzerland, March 26 /PRNewswire-FirstCall/ -- Roche (SWX: ROG.VX; RO.S, OTCQX: RHHBY) announced today that its wholly-owned subsidiary, Roche Investments USA Inc., completed its tender offer for the publicly held shares of Genentech (NYSE: DNA). The offer expired at midnight, New York City time, at the end of Wednesday, March 25. A total of approximately 395.7 million shares of Genentech common stock were tendered representing 84.7% of Genentech's publicly held shares. Roche Investments USA Inc. has accepted for payment all shares validly tendered pursuant to its tender offer.

Together with the 55.7% of the outstanding shares already held by Roche, Roche now holds a total of approximately 982.9 million or 93.2% of the 1,054,555,886 Genentech shares outstanding. In addition, a further 3.0% of Genentech's outstanding shares were guaranteed to be delivered within the next three business days which, if added to the shares already received in the tender offer and Roche's existing stake, would represent approximately 96.2% of Genentech's total outstanding shares. Public shareholders who have tendered their shares will promptly receive $95.00 per share for their shares.

Pursuant to the merger agreement between Roche and Genentech, as soon as practicable Roche will cause a short-form merger under Delaware law in which Genentech will become a wholly-owned member of the Roche Group, and all remaining public shareholders will, subject to appraisal rights, receive $95.00 per share for their shares. Following the merger, Genentech's common stock will cease to be traded on the New York Stock Exchange.

About Roche

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, and is a market leader in virology. It is also active in other major therapeutic areas such as autoimmune diseases, inflammatory and metabolic disorders and diseases of the central nervous system. In 2008 sales by the Pharmaceuticals Division totaled 36.0 billion Swiss francs, and the Diagnostics Division posted sales of 9.7 billion francs. Roche has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai, and invested nearly 9 billion Swiss francs in R&D in 2008. Worldwide, the Group employs about 80,000 people. Additional information is available on the Internet at www.roche.com.

About Genentech

Founded more than 30 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with significant unmet medical needs. The company has headquarters in South San Francisco, California and is listed on the New York Stock Exchange under the symbol DNA. For additional information about the company, please visit http://www.gene.com.

    Roche Group Media Relations
    Phone: +41 61 688 8888 / e-mail: basel.mediaoffice@roche.com
    - Daniel Piller (Head)
    - Alexander Klauser
    - Martina Rupp
    - Claudia Schmitt

    Brunswick Group (for US media)
    Phone: +1 212 333 3810
    - Jennifer Lowney

    MacKenzie Partners, Inc. (for Genentech Investors):
    Phone: +1 212 929 5500
    - Dan Burch
    - Bob Marese


'/>"/>
SOURCE Roche
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Roche and Genentech Reach a Friendly Agreement to Combine the Two Organizations and Create a Leader in Healthcare Innovation
2. SD Canada Announces CE Mark for ThyroChek(R) Adult and NeoNatal Tests
3. Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors
4. Roche Intends to Commence Tender Offer to Acquire All Shares of Genentech for US$ 86.50 Per Share in Cash
5. Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients
6. Roche Purchases Shares in Tender Offer For Memory Pharmaceuticals Corp.
7. Axial Biotech Appoints Retired Roche Diagnostics Executive to Board
8. InformationWeek Puts Roche Diagnostics on Top 500 Innovative Tech Users List
9. Exiqon A/S Today Announces a Grant of License to Roche Diagnostics
10. Roche completes acquisition of ARIUS
11. Affitech Announces Second Milestone in Roche Antibody Discovery Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... Part of 5m$ Investment in Integrated ... ... LLC today announced that it had successfully completed the expansion ... have increased the Screening Collection to over 400,000. The new ... of the company. This expansion, complemented by new robotics and ...
(Date:11/30/2016)... ... 30, 2016 , ... Energetiq Technology, a world leader in ... ultra-bright, Laser-Driven Light Source, the EQ-77, at the MRS Fall Exhibit 2016. , ... higher radiance and irradiance from a truly broadband white light source. The EQ-77 ...
(Date:11/30/2016)... ... ... With growth rates averaging more than 30% each year, Random42 has quickly ... their expansion in their new office space. The new office has a fantastic location ... creative industries, so Random42 Scientific Communication will fit right in. , Ben Ramsbottom, ...
(Date:11/30/2016)... Connecticut , November 30, 2016 ... die integrierte Medikamententdeckung    ... , , ... Prüfbibliothek erfolgreich erweitert zu haben. Zusätzliche 150.000 neuartige Substanzen ... Substanzen wurden sorgfältig ausgewählt, um die starken Entdeckungsfähigkeiten des ...
Breaking Biology Technology:
(Date:11/15/2016)... DUBLIN , Nov 15, 2016 Research ... - Global Forecast to 2021" report to their offering. ... ... reach USD 16.18 Billion by 2021 from USD 6.21 Billion in ... Growth of the bioinformatics market is driven by ...
(Date:6/22/2016)... 22, 2016   Acuant , the ... solutions, has partnered with RightCrowd ® ... Visitor Management, Self-Service Kiosks and Continuous Workforce ... add functional enhancements to existing physical access ... venues with an automated ID verification and ...
(Date:6/15/2016)... 2016 Transparency Market Research ... Market by Application Market - Global Industry Analysis Size Share ... the report, the  global gesture recognition market  was ... is estimated to grow at a CAGR of ... Increasing application of gesture recognition technology ...
Breaking Biology News(10 mins):